Tuberculosis and diabetes mellitus: convergence of two epidemics

Por Dooley, Kelly E, Chaisson, Richard E
Publicado em 2009

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Por Svensson, Elin M., Dooley, Kelly E., Karlsson, Mats O.
Publicado no Antimicrob Agents Chemother (2014)

Pipeline of drugs for related diseases: tuberculosis

Por Dooley, Kelly E., Nuermberger, Eric L., Diacon, Andreas H.
Publicado no Curr Opin HIV AIDS (2013)

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

Por Matteelli, Alberto, Carvalho, Anna CC, Dooley, Kelly E, Kritski, Afranio
Publicado em 2010

TB and HIV Therapeutics: Pharmacology Research Priorities

Por Dooley, Kelly E., Kim, Peter S., Williams, Sharon D., Hafner, Richard
Publicado em 2012

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Por Svensson, Elin M., Murray, Stephen, Karlsson, Mats O., Dooley, Kelly E.
Publicado no J Antimicrob Chemother (2015)

Challenges in the clinical assessment of novel tuberculosis drugs

Por Dooley, Kelly E., Phillips, Patrick P.J., Nahid, Payam, Hoelscher, Michael
Publicado no Adv Drug Deliv Rev (2016)

Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

Por Williamson, Beth, Dooley, Kelly E., Zhang, Yuan, Back, David J., Owen, Andrew
Publicado em 2013

Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis

Por Dooley, Kelly E., Tang, Tania, Golub, Jonathan E., Dorman, Susan E., Cronin, Wendy
Publicado em 2009

Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis

Por Svensson, Elin M., Acharya, Chayan, Clauson, Björn, Dooley, Kelly E., Karlsson, Mats O.
Publicado no AAPS J (2015)

World Health Organization Group 5 Drugs for the Treatment of Drug-Resistant Tuberculosis: Unclear Efficacy or Untapped Potential?

Por Dooley, Kelly E., Obuku, Ekwaro A., Durakovic, Nadza, Belitsky, Vera, Mitnick, Carole, Nuermberger, Eric L.
Publicado em 2013

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice

Por Almeida, Deepak, Converse, Paul J., Ahmad, Zahoor, Dooley, Kelly E., Nuermberger, Eric L., Grosset, Jacques H.
Publicado em 2011

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Por Svensson, Elin M., Aweeka, Francesca, Park, Jeong-Gun, Marzan, Florence, Dooley, Kelly E., Karlsson, Mats O.
Publicado em 2013

Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations

Por Dooley, Kelly, Flexner, Charles, Hackman, Judith, Peloquin, Charles A., Nuermberger, Eric, Chaisson, Richard E., Dorman, Susan E.
Publicado em 2008

Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco

Por Dooley, Kelly E, Lahlou, Ouafae, Ghali, Iraqi, Knudsen, Janine, Elmessaoudi, My Driss, Cherkaoui, Imad, El Aouad, Rajae
Publicado em 2011

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis

Por Alsultan, Abdullah, Savic, Rada, Dooley, Kelly E., Weiner, Marc, Whitworth, William, Mac Kenzie, William R., Peloquin, Charles A.
Publicado no Antimicrob Agents Chemother (2017)

Population Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Healthy Volunteers: Nonlinearities in Clearance and Bioavailability

Por Savic, Radojka M., Lu, Yanhui, Bliven-Sizemore, Erin, Weiner, Marc, Nuermberger, Eric, Burman, William, Dorman, Susan E., Dooley, Kelly E.
Publicado em 2014

T-SPOT.TB responses during treatment of pulmonary tuberculosis

Por Ribeiro, Samantha, Dooley, Kelly, Hackman, Judith, Loredo, Carla, Efron, Anne, Chaisson, Richard E, Conde, Marcus B, Boechat, Neio, Dorman, Susan E
Publicado em 2009

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis

Por Kaushik, Amit, Ammerman, Nicole C., Tasneen, Rokeya, Story-Roller, Elizabeth, Dooley, Kelly E., Dorman, Susan E., Nuermberger, Eric L., Lamichhane, Gyanu
Publicado no J Antimicrob Chemother (2017)

Quantification of Rifapentine, a Potent Antituberculosis Drug, from Dried Blood Spot Samples Using Liquid Chromatographic-Tandem Mass Spectrometric Analysis

Por Parsons, Teresa L., Marzinke, Mark A., Hoang, Thuy, Bliven-Sizemore, Erin, Weiner, Marc, Mac Kenzie, William R., Dorman, Susan E., Dooley, Kelly E.
Publicado no Antimicrob Agents Chemother (2014)